Home › Flamel Technologies Announces FDA Approval Of Bloxiverz
 

Keywords :   


Flamel Technologies Announces FDA Approval Of Bloxiverz

2013-06-05 07:22:35| drugdiscoveryonline News Articles

Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for Bloxiverz™ (neostigmine methylsulfate), a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery

Tags: technologies approval announces fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
25.06Royal Mail buyer to make offer for all staff shares
25.06Hybrid Software wins FLAG Vendor Partner of the Year award
25.06Hospeco Purchases Nuance Solutions
25.06Atlantic Tropical Weather Outlook
25.06DNA Genetics opens new commercial sow research farm
25.06Eastern North Pacific Tropical Weather Outlook
25.06Briolf Group to Invest $30 Million in Its First US Production Plant
25.06IDENTCO rebrands TTL200 Series to DuraWrap and DuraFlag
More »